These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32037726)

  • 1. Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents.
    Matos MJ; Herrera Ibatá DM; Uriarte E; Viña D
    ChemMedChem; 2020 Mar; 15(6):532-538. PubMed ID: 32037726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin-Coumarin Hybrid Analogues as Multitarget Agents in Neurodegenerative Disorders.
    Quezada E; Rodríguez-Enríquez F; Laguna R; Cutrín E; Otero F; Uriarte E; Viña D
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
    Xie SS; Liu J; Tang C; Pang C; Li Q; Qin Y; Nong X; Zhang Z; Guo J; Cheng M; Tang W; Liang N; Jiang N
    Eur J Med Chem; 2020 Sep; 202():112475. PubMed ID: 32652406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
    Tao D; Wang Y; Bao XQ; Yang BB; Gao F; Wang L; Zhang D; Li L
    Eur J Med Chem; 2019 Jul; 173():203-212. PubMed ID: 31005056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
    Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
    Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
    Pisani L; Farina R; Catto M; Iacobazzi RM; Nicolotti O; Cellamare S; Mangiatordi GF; Denora N; Soto-Otero R; Siragusa L; Altomare CD; Carotti A
    J Med Chem; 2016 Jul; 59(14):6791-806. PubMed ID: 27347731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
    Rodríguez-Enríquez F; Costas-Lago MC; Besada P; Alonso-Pena M; Torres-Terán I; Viña D; Fontenla JÁ; Sturlese M; Moro S; Quezada E; Terán C
    Bioorg Chem; 2020 Nov; 104():104203. PubMed ID: 32932120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
    Liu L; Chen Y; Zeng RF; Liu Y; Xie SS; Lan JS; Ding Y; Yang YT; Yang J; Zhang T
    Bioorg Chem; 2021 Apr; 109():104685. PubMed ID: 33640631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Amidocoumarins as Potential Multifunctional Agents against Neurodegenerative Diseases.
    Matos MJ; Rodríguez-Enríquez F; Borges F; Santana L; Uriarte E; Estrada M; Rodríguez-Franco MI; Laguna R; Viña D
    ChemMedChem; 2015 Dec; 10(12):2071-9. PubMed ID: 26493007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
    Xiao X; Zhang XX; Zhan MM; Cheng K; Li S; Xie Z; Liao C
    Eur J Med Chem; 2018 Feb; 145():588-593. PubMed ID: 29339253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Amidocoumarins as Multitarget Agents against Neurodegenerative Diseases: Substitution Pattern Modulation.
    Rodríguez-Enríquez F; Viña D; Uriarte E; Laguna R; Matos MJ
    ChemMedChem; 2021 Jan; 16(1):179-186. PubMed ID: 32700464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease.
    Li W; Yang X; Song Q; Cao Z; Shi Y; Deng Y; Zhang L
    Bioorg Chem; 2020 Apr; 97():103707. PubMed ID: 32146176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
    Secci D; Carradori S; Bolasco A; Chimenti P; Yáñez M; Ortuso F; Alcaro S
    Eur J Med Chem; 2011 Oct; 46(10):4846-52. PubMed ID: 21872365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
    Chavarria D; Fernandes C; Silva V; Silva C; Gil-Martins E; Soares P; Silva T; Silva R; Remião F; Oliveira PJ; Borges F
    Eur J Med Chem; 2020 Jan; 185():111770. PubMed ID: 31711793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
    Dhiman P; Malik N; Khatkar A
    Curr Top Med Chem; 2018; 18(21):1857-1871. PubMed ID: 30430943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
    Kong H; Meng X; Hou R; Yang X; Han J; Xie Z; Duan Y; Liao C
    Bioorg Med Chem Lett; 2021 Jul; 43():128051. PubMed ID: 33887441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.